LEXINGTON, Mass., Oct. 20, 2018 /PRNewswire/ -- Agenus
Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies, cancer vaccines, and adoptive cell
therapies2, presented updated clinical data on its lead
CTLA-4 and PD-1 programs today at the 2018 European Society for
Medical Oncology (ESMO) Congress, in Munich, Germany.
"We have initiated expanded clinical trials designed for
potential approval of our proprietary PD-1 and CTLA-4 antibodies in
second line cervical cancer," said Garo
Armen, Ph.D., Chairman and CEO of Agenus. "We are pursuing
both monotherapy and combination trials as a dual track regulatory
strategy with a planned BLA filing as early as 2020."
Data presented at ESMO is based on 76 patients treated with
PD-1 (AGEN2034) as well as combination PD-1 and CTLA-4 (AGEN1884)
regimens.
- Agenus' anti-PD-1 (AGEN2034) and CTLA-4 (AGEN1884) reveal
clinical activity across multiple solid tumors, including breast
and gynecologic cancers such as cervical and ovarian.
- Patients treated with AGEN2034 reveal a clinical benefit rate
of 68% in evaluable patients with metastatic and/or locally
advanced solid tumors, and in 3 of 7 evaluable patients with
refractory cervical cancer.
- Data from combination AGEN2034 plus AGEN1884 show similar
trends; early clinical benefit observed in 7 of 16 evaluable
patients with ovarian, breast, and soft tissue sarcoma, including a
durable response in a patient with ovarian cancer.
Since the ESMO data cut-off, early evidence of clinical
benefit was observed in patients with cervical cancer treated with
combination AGEN2034 and AGEN1884. ESMO posters are
available
at http://agenusbio.com/technology/publications/
1Clinical benefit is defined as complete
response, partial response and/or disease
stabilization
2Through AgenTus
Therapeutics, a subsidiary of Agenus
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, proprietary
cancer vaccine platforms, and adoptive cell therapies (through its
AgenTus Therapeutics subsidiary). The Company is equipped with a
suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' clinical
development plans and timelines, potential BLA filings and
timelines and anticipated clinical benefit in future clinical trial
results. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including the risk that preliminary results may not be indicative
of final results or results of future clinical trials. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-presents-clinical-data-on-its-pd-1--ctla-4-at-esmo-2018-300734715.html
SOURCE Agenus Inc.